Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ananda Developments - Ananda Developments Epilepsy Trials
Details : MRX2 (cannabidiol) is a CB1 negative allosteric modulator, small molecule drug candidate, which is indicated for the treatment of refractory early-onset Epilepsy.
Product Name : MRX2
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 21, 2024
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable